[{"orgOrder":0,"company":"Bone Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation\n","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"rhNELL-1","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Bone Biologics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bone Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bone Biolo.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposa\n","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Liverpool School of Tropical Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers at LSTM Demonstrate a Novel Way to Treat Snakebite","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimercaprol","moa":"Heavy metal","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Liverpool School of Tropical Medicine","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Liverpool School of Tropical Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Liverpool .."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 004","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Surrozen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen\u2019s Novel Wnt Activating Antibodies","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Wnt Activating Antibodies","moa":"WNT signalling pathway","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Surrozen","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Kantum Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kantum Pharma Highlights New Research Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KB-1801","moa":"P2Y14 receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kantum Pharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kantum Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kantum Pha.."},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mission Raises $15m and Expands its Relationship with Pfizer","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"USP30","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Mission Therapeutics","amount2":0.02,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"Mission Th.."},{"orgOrder":0,"company":"NeurAegis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeurAegis Announces Publication of Preclinical Animal Data Supporting Calpain-2 as a Promising Therapeutic Target for Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Calpain-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeurAegis","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeurAegis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeurAegis .."},{"orgOrder":0,"company":"Versameb","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"Versameb Raises CHF 6 Million and Strengthens Team to Advance its VERSagile Technology Platform Towards Clinical Trials","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Financing","leadProduct":"RNA based therapies","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Versameb","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Versameb \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/.."},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Mydecine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Leiden University Medical Center","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leiden University Medical Center \/ Mydecine","highestDevelopmentStatusID":"4","companyTruncated":"Leiden Uni.."},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"AV-001","moa":"Angiopoietin 1","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vasomune Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vasomune Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Vasomune T.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atai Life Sciences Launches Empath Bio to Treat Post-Traumatic Stress Disorder with Novel Mdma Product","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methamphetamine Hydrochloride","moa":"Serotonin","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAxone BioSciences Announces Notice of Allowance that Expands Scope of Key ROCK Inhibitors for Treatment of Cerebral Aneurysms","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BA-1049","moa":"Rho-associated protein kinase 2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAxone BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone B.."},{"orgOrder":0,"company":"Tikomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tikomed's ILB\u00ae Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextrans","moa":"MMP","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tikomed","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tikomed \/ .."},{"orgOrder":0,"company":"Rutgers University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rutgers University's New Smart Drug Delivery System May Help Treatment for Neurological Disorders","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Rutgers University","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Rutgers University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rutgers Un.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Positive Preclinical Data on JadiCell\u2122 Universal Donor Stem Cell Therapy for Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Meabco","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"Meabco Gets $5.9 M US Government Contract to Advance Its Bp-C2 Compound for Cutaneous Radiation Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"BP-C2","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Meabco \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ N.."},{"orgOrder":0,"company":"Meabco","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meabco's Drug Candidate Efficiently Mitigates Radiation-Induced Gastrointestinal Syndrome in Mice","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BP-C2","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meabco \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ N.."},{"orgOrder":0,"company":"Medicinova","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Presentation of Positive Findings on MN-001 in Acute Liver Injury Model at The Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipelukast","moa":"5-LO","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"NASA","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enzychem Lifesciences Receives NASA Grant Funding to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ NASA","highestDevelopmentStatusID":"4","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Walter Reed Army Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noveome Biotherapeutics and Walter Reed Army Institute of Research to Study Noveome\u2019s Lead Product Candidate ST266 in Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"intranasal","sponsorNew":"Noveome Biotherapeutics \/ Walter Reed Army Institute","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Tellus Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"TT-20","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tellus Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tellus Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Tellus The.."},{"orgOrder":0,"company":"Ischemix","sponsor":"US Department of Defense","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Ischemix Receives US DoD Funding of $2.9M to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Funding","leadProduct":"CMX-2043","moa":"Akt phosphorylation","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Ischemix","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ischemix \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Ischemix \/.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Completes FDA Requested Studies to Initiate JadiCell\u2122 Chronic Traumatic Encephalopathy","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"BioCurity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCurity Pharmaceuticals Inc. ('BioCurity' or \u2018Company\u2019) Expanding Patent Portfolio Successes for Supportive Cancer Drugs Designed to Prevent Radiation Therapy Side Effects","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cerium Oxide","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioCurity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioCurity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCurity .."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatment of Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Incannex","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"Aruna Bio","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aruna Bio Advances Therapeutic Development for Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"AB126","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aruna Bio \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio .."},{"orgOrder":0,"company":"Aruna Bio","sponsor":"University of Georgia Research Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruna Bio Announces Issuance Of A New Composition Of Matter Patent Covering Neural Exosomes In Japan","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AB126","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aruna Bio \/ University of Georgia Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio .."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"LTBP-TGF beta 1","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Curia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Incannex Healthcare \/ Curia Global","highestDevelopmentStatusID":"4","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Kane Biotech","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB\u00ae Hydrogel from the United States Department of Defense","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"DispersinB","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biote.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Opaganib","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer\u2122s Disease","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"INmune Bio \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoImmuneTech to Partner with U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for Drug Development in Acute Radiation Syndrome (ARS)","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Efineptakin Alfa","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NeoImmuneTech \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United States Patent Office Allows Patent to Exosome Biomedical Company Nurexone","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Biologically-guided Exosome Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Vixarelimab","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kiniksa Pharmaceuticals","amount2":0.69999999999999996,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Opaganib","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Biologically-guided Exosome Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Mediar Therapeutics","amount2":0.11,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Mediar Therapeutics \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Mediar The.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ATYR0101","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Mississippi State University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Halberd Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Halberd Corporation \/ Mississippi State University","highestDevelopmentStatusID":"4","companyTruncated":"Halberd Co.."},{"orgOrder":0,"company":"Ceapro","sponsor":"Angiogenesis Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Oat Beta Glucan","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ceapro \/ Angiogenesis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ A.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Biologically-guided Exosome Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"CSIRO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amplia Receives Grant to Collaborate with CSIRO \u2013 Supplementary Announcement","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"AMP945","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Amplia Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amplia Therapeutics \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"Amplia The.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"AMRMC","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Receives Army Medical Research Grant for Study on Mild Traumatic Brain Injury (mTBI) from Blast Induced Functional Deficit and Brain Pathology","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Galantamine Prodrug","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Cognition \/ AMRMC","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"HempMeds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medical Marijuana, Inc. Participates in Preclinical Research Study on Therapeutic Benefits of CBD on Traumatic Brain Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"HempMeds","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oil","sponsorNew":"HempMeds \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"HempMeds \/.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Israeli Shekels","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"ExoTherapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Israeli Shekels","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Mississippi State University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halberd Corporation Plans to Extend Research Partnership with Mississippi State University","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Halberd Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Halberd Corporation \/ Mississippi State University","highestDevelopmentStatusID":"4","companyTruncated":"Halberd Co.."},{"orgOrder":0,"company":"InGeneron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Transpose RT Cell Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"InGeneron","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InGeneron \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"InGeneron .."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Biologically-guided Exosome Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"ExoPTEN","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Vivox","sponsor":"NurExone Biologic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for its Spinal Cord Injury Therapy, ExoPTEN","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"ExoPTEN","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vivox","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivox \/ NurExone Biologic","highestDevelopmentStatusID":"4","companyTruncated":"Vivox \/ Nu.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"ExoPTEN","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Recursion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ExoPTEN","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Kalinga Institute of Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Supriya Lifescience Signs Agreement with KIT for Further Development of Wound Healing Gel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Protein-based Crosslinked Hydrogel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Supriya Lifescience","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Supriya Lifescience \/ Kalinga Institute of Technology","highestDevelopmentStatusID":"4","companyTruncated":"Supriya Li.."}]
Find Drugs for Trauma (Emergency, Injury, Surgery) in Preclinical Development